Next Article in Journal
Assessment of Influenza D Virus in Domestic Pigs and Wild Boars in France: Apparent Limited Spread within Swine Populations Despite Serological Evidence of Breeding Sow Exposure
Next Article in Special Issue
Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill
Previous Article in Journal
Viral Equine Encephalitis, a Growing Threat to the Horse Population in Europe?
Previous Article in Special Issue
When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses
Open AccessReview

Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination

1
College of Veterinary Medicine, Jeju National University, Jeju 63243, Korea
2
Interdisciplinary Graduate Program in Advanced Convergence Technology & Science, Jeju National University, Jeju 63243, Korea
3
Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
*
Authors to whom correspondence should be addressed.
Viruses 2020, 12(1), 24; https://doi.org/10.3390/v12010024
Received: 20 November 2019 / Revised: 12 December 2019 / Accepted: 20 December 2019 / Published: 24 December 2019
(This article belongs to the Special Issue Dendritic Cells and Antiviral Defense)
Dendritic cells (DCs) are involved in human and simian immunodeficiency virus (HIV and SIV) pathogenesis but also play a critical role in orchestrating innate and adaptive vaccine-specific immune responses. Effective HIV/SIV vaccines require strong antigen-specific CD4 T cell responses, cytotoxic activity of CD8 T cells, and neutralizing/non-neutralizing antibody production at mucosal and systemic sites. To develop a protective HIV/SIV vaccine, vaccine regimens including DCs themselves, protein, DNA, mRNA, virus vectors, and various combinations have been evaluated in different animal and human models. Recent studies have shown that DCs enhanced prophylactic HIV/SIV vaccine efficacy by producing pro-inflammatory cytokines, improving T cell responses, and recruiting effector cells to target tissues. DCs are also targets for therapeutic HIV/SIV vaccines due to their ability to reverse latency, present antigen, and augment T and B cell immunity. Here, we review the complex interactions of DCs over the course of HIV/SIV prophylactic and therapeutic immunizations, providing new insights into development of advanced DC-targeted HIV/SIV vaccines. View Full-Text
Keywords: dendritic cells; human/simian immunodeficiency virus; vaccine; antigen-specific responses dendritic cells; human/simian immunodeficiency virus; vaccine; antigen-specific responses
MDPI and ACS Style

Ko, E.-J.; Robert-Guroff, M. Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination. Viruses 2020, 12, 24.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop